Posted on May 18, 2019 by Sitemaster
We have noted several times in the past that, at least to date, compared to the results shown by the PD-1 and PD-L1 checkpoint inhibitors in the treatment of cancers like lung cancer, kidney cancer, and melanoma, there has been little evidence of the value of these agents in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: atezolizumab. Keytruda, HSPC, mCRPC, nivolumab, Opdivo, PD-1, PD-L1, pembrolizumab, Tecentriq | 7 Comments »
Posted on April 5, 2019 by Sitemaster
So some readers will already have seen the article in today’s New York Times entitled “Cancer’s trick for dodging the immune system“. … READ MORE …
Filed under: Uncategorized | Tagged: cure, exosome, laboratory, mice, PD-L1 | 4 Comments »
Posted on March 29, 2019 by Sitemaster
We have heard a lot about treatment with checkpoint inhibitors over the past two or three years. When they work well, they can work very well indeed, but these drugs come with significant risk for side effects, and some of those side effects can be very serious. … READ MORE …
Filed under: Uncategorized | Tagged: checkpoint, CTLA4, immunotherapy, inhibition, PD-1, PD-L1, risk | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 